Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial-Reference-Cited by-同舟云学术

Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial

Published:2013-06 Issue:7 Volume:14 Page:663-670
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Amadori Dino,Aglietta Massimo,Alessi Barbara,Gianni Lorenzo,Ibrahim Toni,Farina Gabriella,Gaion Fernando,Bertoldo Francesco,Santini Daniele,Rondena Roberta,Bogani Paola,Ripamonti Carla I

Publisher

Elsevier BV

Subject

Oncology

Reference31 articles.

1. Bisphosphonates: clinical experience;Coleman;Oncologist,2004

2. The bone microenvironment in metastasis; what is special about bone?;Bussard;Cancer Metastasis Rev,2008

3. Skeletal complications of malignancy;Coleman;Cancer,1997

4. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials;Lipton;Cancer,2000

Cited by 176 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study;Journal of Clinical Oncology;2024-08-20

2. A randomised trial comparing 6-monthly adjuvant zoledronate with a single one-time dose in patients with early breast cancer;Breast Cancer Research and Treatment;2024-07-31

3. Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies;ESMO Open;2024-07

4. Bone-modifying agents for bone metastasis in patients with breast cancer;Kosin Medical Journal;2024-06-30

5. Exploring the Clinical Impact of RANK Pathway Inhibition in Advanced Breast Cancer: Insights From a Retrospective Study on CDK4/6 Inhibitors and Antiresorptive Therapy;Cureus;2024-06-28